Nitrogen, Other Than As Nitro Or Nitroso, Attached Directly Or Indirectly To The Acridine Ring System By Nonionic Bonding Patents (Class 546/104)
  • Publication number: 20100112545
    Abstract: Novel trans-1,2-diphenylethylene derivatives are synthesized which can be used to form nanoparticles-monomer-nanomolecule-receptor nanosensors. These trans-1,2-diphenyl-ethylene derivatives are soluble in both water and organic solvents, highly fluorescent and can be synthesized in high yields. The trans-1,2-diphenylethylene derivatives are bonded to a nanoparticle, a nanomolecule bonded to the derivative and a receptor bonded to the nanomolecule to form a nanosensor that can be used to detect chemical and biological agents.
    Type: Application
    Filed: July 13, 2007
    Publication date: May 6, 2010
    Inventors: Subra Muralidharan, Chun Wang
  • Publication number: 20100061928
    Abstract: The present invention relates to the use of a compound of formula (I): in which R1 represents a radionuclide, Ar represents an aromatic nucleus, m is an integer varying from 2 to 4, R2 and R3 represent, independently of one another, a hydrogen atom, a (C1-C6)alkyl group, a (C1-C6)alkenyl group or an aryl group chosen from a phenyl, benzyl, imidazolyl, pyridyl, pyrimidinyl, pyrazinyl, indolyl, indazolyl, furyl and thienyl group, and their addition salts with pharmaceutically acceptable acids, in the preparation of a radiopharmaceutical composition intended for the diagnosis and/or treatment of melanoma.
    Type: Application
    Filed: July 27, 2007
    Publication date: March 11, 2010
    Applicants: Institut National De La Sante et De La Recherche Medicale (INSERM), Universite D'Auvergne Clermont 1
    Inventors: Jean-Claude Madelmont, Jean-Michel Chezal, Nicole Moins, Jean-Claude Teulade, Olivier Chavignon
  • Publication number: 20090264463
    Abstract: Inhibitors of Protein Phosphatase-1 have been shown to slow replication of HIV-1. Inhibitors of PP 1 and their use for treatment or prevention of HIV-1 infections are disclosed.
    Type: Application
    Filed: April 15, 2009
    Publication date: October 22, 2009
    Inventors: Sergei Nekhai, Dmytro Borysovich Kovalskyy
  • Publication number: 20090186155
    Abstract: An ink for ink-jet recording includes a luminescence marker which emits light by oxidization. It may be determined whether the ink for ink-jet recording is used for recording the ink-jet recorded object with a simple method such as an evaluation of luminescence by oxidation, without requiring a special equipment.
    Type: Application
    Filed: January 21, 2009
    Publication date: July 23, 2009
    Applicant: BROTHER KOGYO KABUSHIKI KAISHA
    Inventor: Michiko Aoyama
  • Patent number: 7511064
    Abstract: The present invention relates to derivatives of 4-(Thio- or Selenoxanthene-9-ylidene)-piperidine or acridine and pharmaceutically acceptable salts thereof, use of these compounds as a medicament and for the manufacture of a medicament for treatment of a disease state which can be alleviated by treatment with a 5-HT2B antagonist.
    Type: Grant
    Filed: April 19, 2006
    Date of Patent: March 31, 2009
    Assignee: Biofrontera Bioscience GmbH
    Inventors: Hermann Lubbert, Christoph Ullmer, Emile Bellott, Mark Froimowitz, Douglas Gordon
  • Publication number: 20090074673
    Abstract: The disclosure provides, in part, compositions and methods for producing cellular labels for tracking cells by MRI. The disclosure provides, in part, methods for labeling, detecting and quantifying cell numbers in vivo.
    Type: Application
    Filed: July 10, 2008
    Publication date: March 19, 2009
    Applicant: Carnegie Mellon University
    Inventors: Jelena Janjic, Eric T. Ahrens
  • Patent number: 7442790
    Abstract: This invention provides caspase inhibitors of formula I: wherein Z is oxygen or sulfur; R1 is hydrogen, —CHN2, R, CH2OR, CH2SR, or —CH2Y; between R3 and R4 represents a single or double bond; Y is an electronegative leaving group; R2 is CO2H, CH2CO2H, or esters, amides or isosteres thereof; R3is a group capable of fitting into the S2 subsite of a caspase enzyme; R4 is a hydrogen or C1-6 alkyl or R3 and R4 taken together form a ring; Ring A and Ring B are each heterocyclic rings, and R and R5 are as described in the specification. The compounds are effective inhibitors of apoptosis and IL-1? secretion.
    Type: Grant
    Filed: June 28, 2007
    Date of Patent: October 28, 2008
    Assignee: Vertex Pharmaceuticals, Incorporated
    Inventors: Michael Mortimore, Andrew Miller, John Studley, Jean-Damien Charrier
  • Publication number: 20080199973
    Abstract: In accordance with the present invention, it has been discovered that introduction of hydrophilic sulfoalkyl substituents and/or hydrophilic linkers derived from homocysteic acid, cysteic acid, glycine peptides, tetraethylene oxide, and the like, offset the hydrophobicity of the acridinium ring system to produce a more soluble label which can be attached to an antibody at higher loading before precipitation and aggregation problems are encountered. Additional compounds described herein contain linkers derived from short peptides and tetraethylene oxide which increase aqueous solubility due to hydrogen bonding with water molecules. The present invention also embraces reagents for multiple acridinium labeling for signal amplification composed of a peptide bearing several acridinium esters with sulfonate groups at regularly spaced intervals for increased solubility. The invention also embraces assays employing the above-described compounds.
    Type: Application
    Filed: November 7, 2007
    Publication date: August 21, 2008
    Inventors: Ramon Evangelista, Martha Garrity
  • Patent number: 7351807
    Abstract: Dye-sulfenate derivatives and their bioconjugates for dual phototherapy of tumors and other lesions.
    Type: Grant
    Filed: July 3, 2001
    Date of Patent: April 1, 2008
    Assignee: Mallinckrodt Inc.
    Inventors: Raghavan Rajagopalan, Samuel I. Achilefu, Joseph E. Bugaj, Richard B. Dorshow
  • Patent number: 7300930
    Abstract: The present invention pertains to acridone and acridine compounds of formula (I), wherein either: (a) K is ?O, L is —H, alpha is a single bond, beta is a double bond, gamma is a single bond (acridones); or, (b) K is a 9-substituent, L is absent, alpha is a double bond, beta is a single bond, gamma is a double bond (acridines); and wherein: J1 is a 2- or 3-substituent; J2 is a 6- or 7-substituent; J1 and J2 are each independently a group of the formula —NHCO(CH2)nNR1R2, wherein: n is an integer from 1 to 5; and, R1 and R2 are independently hydrogen, C1-7alkyl, C3-20heterocyclyl, or C5-20aryl, or R1 and R2, taken together with the nitrogen atom to which they are attached, form a heterocyclic ring having from 3 to 8 ring atoms; and wherein, when K is a 9-substituent, K is a group of the formula —N(RN)Q, wherein: RN is an amino substituent and is hydrogen, C1-7alkyl, C3-20heterocyclyl, or C5-20aryl; and, Q is C1-7alkyl, C3-20heterocyclyl, or C5-20aryl, and is optionally substituted; and pharmaceutically acceptabl
    Type: Grant
    Filed: June 22, 2005
    Date of Patent: November 27, 2007
    Assignee: Cancer Research Technology Limited
    Inventors: Stephen Neidle, Richard John Harrison, Lloyd Royston Kelland, Sharon Michele Gowan, Martin Anthony Read, Anthony Reszka
  • Patent number: 7297555
    Abstract: In accordance with the present invention, it has been discovered that introduction of hydrophilic sulfoalkyl substituents and/or hydrophilic linkers derived from homocysteic acid, cysteic acid, glycine peptides, tetraethylene oxide, and the like, offset the hydrophobicity of the acridinium ring system to produce a more soluble label which can be attached to an antibody at higher loading before precipitation and aggregation problems are encountered. Additional compounds described herein contain linkers derived from short peptides and tetraethylene oxide which increase aqueous solubility due to hydrogen bonding with water molecules. The present invention also embraces reagents for multiple acridinium labeling for signal amplification composed of a peptide bearing several acridinium esters with sulfonate groups at regularly spaced intervals for increased solubility. The invention also embraces assays employing the above-described compounds.
    Type: Grant
    Filed: July 14, 2005
    Date of Patent: November 20, 2007
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Ramon Evangelista, Martha Garrity
  • Patent number: 7122671
    Abstract: A compound for use as a chemiluminescent label in immunoassay comprises an aryl acridinium ester linked to an N-succinimidyl moiety. The compound is conveniently linked to a monoclonal antibody or other protein and is used in a two-site immunoassay for the quantitation of an antigen of interest, by initiation of the luminescent reaction and subsequent measurement of the photonic emission of the immune complex formed during the immunological reaction.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: October 17, 2006
    Assignee: University College Cardiff Consultants Limited
    Inventors: Anthony Keith Campbell, James Stuart Woodhead, Ian Weeks
  • Patent number: 7060711
    Abstract: The present invention relates to derivatives of 4-(Thio- or Selenoxanthene-9-ylidene)-piperidine or acridine and pharmaceutically acceptable salts thereof, use of these compounds as a medicament and for the manufacture of a medicament for treatment of a disease state which can be alleviated by treatment with a 5-HT2B antagonist.
    Type: Grant
    Filed: October 25, 2002
    Date of Patent: June 13, 2006
    Assignee: Biofrontera Bioscience GmbH
    Inventors: Hermann Lubbert, Christoph Ullmer, Emile Bellott, Mark Froimowitz, Douglas Gordon
  • Patent number: 7041674
    Abstract: A compound of formula 1 wherein X?, A, R1, R2, R3, and R4 may have the meanings given in the claims and in the specification, processes for preparing them, their use in pharmaceutical compositions, and methods of treating patients using them.
    Type: Grant
    Filed: November 20, 2003
    Date of Patent: May 9, 2006
    Assignee: Boehringer Ingelhiem Pharma GmbH & Co. KG
    Inventors: Steffen Breitfelder, Matthias Hoffmann, Matthias Grauert, Michael P. Pieper, Georg Speck
  • Patent number: 6995262
    Abstract: The invention relates to a novel polymethine dyes containing at least one acylsulfonamido group of the formula (I) in which n, Y, A and R have the meaning given in the claims, and at least one compound of the formulae (a) to (n) given in the claims. The polymethine dyes according to the invention are suitable for use as dyes and/or labels, in particular for staining or labeling biomolecules.
    Type: Grant
    Filed: July 24, 2000
    Date of Patent: February 7, 2006
    Assignee: Bayer CropScience AG
    Inventors: Geert Deroover, Michael Missfeldt, Lydia Simon
  • Patent number: 6994980
    Abstract: A novel chemiluminescent compound is provided. In one embodiment, the novel compound is employed in an assay to detect analytes. The assay to detect analytes includes the steps of binding the novel compound to the analyte and detecting the novel compound.
    Type: Grant
    Filed: March 22, 2004
    Date of Patent: February 7, 2006
    Assignee: Quest Diagnostics Investments Inc.
    Inventors: Phillip P. Miller, Martha Garrity
  • Patent number: 6924373
    Abstract: The present invention relates to DNA labeling reagents comprising a furocoumarin derivative and a detectable group with or without bound via a binding enhancer, and acridinium-9-carboxamide derivatives for use as chemiluminescent labels. The present invention also relates to a process of preparing DNA labeling compound.
    Type: Grant
    Filed: May 2, 2003
    Date of Patent: August 2, 2005
    Assignee: AsiaGen Corporation
    Inventors: George Chin-Sheng Chou, Yu-Cheng Wu, Po-Ya Hsu
  • Patent number: 6924154
    Abstract: In accordance with the present invention, it has been discovered that introduction of hydrophilic sulfoalkyl substituents and/or hydrophilic linkers derived from homocysteic acid, cysteic acid, glycine peptides, tetraethylene oxide, and the like, offset the hydrophobicity of the acridinium ring system to produce a more soluble label which can be attached to an antibody at higher loading before precipitation and aggregation problems are encountered. Additional compounds described herein contain linkers derived from short peptides and tetraethylene oxide which increase aqueous solubility due to hydrogen bonding with water molecules. The present invention also embraces reagents for multiple acridinium labeling for signal amplification composed of a peptide bearing several acridinium esters with sulfonate groups at regularly spaced intervals for increased solubility. The invention also embraces assays employing the above-described compounds.
    Type: Grant
    Filed: August 20, 2002
    Date of Patent: August 2, 2005
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Ramon Evangelista, Martha Garrity
  • Patent number: 6872828
    Abstract: Novel compounds comprising a C—C double bond substituted at one carbon with two sulfur atom-containing groups are disclosed. The compounds are useful in methods and compositions for generating chemiluminescence rapidly by reaction with a peroxidase enzyme and a peroxide. The chemiluminescence thus produced can be used as a detectable signal in assays for peroxidase enzymes or peroxide-producing enzymes and in assays employing enzyme-labeled specific binding pairs.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: March 29, 2005
    Assignee: Lumigen, Inc.
    Inventors: Hashem Akhavan-Tafti, Renuka de Silva, Wenhua Xie
  • Patent number: 6858162
    Abstract: Diodes and switches are combined in a single molecular species. Thus, the single molecular species is capable of performing more than one function. A single molecular species having both diode and switch functionalities is provided. The molecular species is represented by the formula: where A and B are non-identical conducting moieties, I is an insulating bridge between A and B, CL and CR are connectors to left and right electrodes, respectively, and “+” and “?” represent a rotatable dipolar moiety. Further, a diode-switch combination is provided, comprising the single molecular species. The teachings herein provide a set of principles to combine diodes and switches within one molecular species. Further, with the present teachings, only a single molecular species is needed for the fabrication of viable moletronic devices such as crossbar memory arrays. Consequently, device fabrication is easier and cheaper, and the device itself less faulty and more reliable.
    Type: Grant
    Filed: April 1, 2002
    Date of Patent: February 22, 2005
    Assignee: Hewlett-Packard Development Company, L.P.
    Inventor: Pavel Kornilovich
  • Patent number: 6858733
    Abstract: Novel compounds comprising a C—C double bond substituted at one carbon with two sulfur atom-containing groups are disclosed. The compounds are useful in methods and compositions for generating chemiluminescence rapidly by reaction with a peroxidase enzyme and a peroxide. The chemiluminescence thus produced can be used as a detectable signal in assays for peroxidase enzymes or peroxide-producing enzymes and in assays employing enzyme-labeled specific binding pairs.
    Type: Grant
    Filed: July 25, 2002
    Date of Patent: February 22, 2005
    Assignee: Lumigen, Inc.
    Inventors: Hashem Akhavan-Tafti, Renuka de Silva, Wenhua Xie
  • Patent number: 6858742
    Abstract: The present invention relates to DNA labeling reagents comprising a furocoumarin derivative and a detectable group with or without bound via a binding enhancer, and acridinium-9-carboxamide derivatives for use as chemiluminescent labels. The present invention also relates to a process of preparing DNA labeling compound.
    Type: Grant
    Filed: October 22, 2003
    Date of Patent: February 22, 2005
    Assignee: AsiaGEN Corporation
    Inventors: George Chin-Sheng Chou, Yu-Cheng Wu, Po-Ya Hsu
  • Patent number: 6800656
    Abstract: The present invention provides a compound of the formula and pharmaceutically acceptable salts having useful antiviral activity against viruses of the herpes family. Wherein: X=O, (CH2)m, S, SO, SO2, NH, NR8; Y=O, (CH2)m, S, SO, SO2, NH, NR8 or a chemical bond; Z=NH, O, NR8, S, SO, SO2; The remaining substituents are described in the specification.
    Type: Grant
    Filed: July 5, 2002
    Date of Patent: October 5, 2004
    Assignee: Warner Lambert Company
    Inventors: Richard John Booth, Vara Prasad Venkata Nagendra Josyula, Annette Lynn Meyer, Bruce Allan Steinbaugh
  • Publication number: 20040122233
    Abstract: Bistable molecules are provided with at least one photosensitive functional group. As thus constituted, the bistable molecules are photopatternable, thereby allowing fabrication of micrometer-scale and nanometer-scale circuits in discrete areas without relying on a top conductor as a mask. The bistable molecules may comprise molecules that undergo redox reactions, such as rotaxanes and catenanes, or may comprise molecules that undergo an electric-field-induced band gap change that causes the molecules, or a portion thereof, to rotate, bend, twist, or otherwise change from a substantially fully conjugated state to a less conjugated state. The change in states in the latter case results in a change in electrical conductivity.
    Type: Application
    Filed: October 30, 2003
    Publication date: June 24, 2004
    Inventors: Patricia A. Beck, Xiao-An Zhang, Zhang-Lin Zhou
  • Patent number: 6740649
    Abstract: The present application describes novel cyclic hydroxamic acids of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NR1, and S(O)p, and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-&agr; converting enzyme (TACE), aggrecanase or a combination thereof, pharmaceutical compositions containing the same, and methods of using the same.
    Type: Grant
    Filed: September 16, 2002
    Date of Patent: May 25, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gregory R. Ott, Xiao-Tao Chen, Jingwu Duan, Zhonghui Lu
  • Patent number: 6723851
    Abstract: A novel chemiluminescent compound is provided. In one embodiment, the novel compound is employed in an assay to detect analytes. The assay to detect analytes includes the steps of binding the novel compound to the analyte and detecting the novel compound.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: April 20, 2004
    Assignee: Quest Diagnostics Investment Incorporated
    Inventors: Phillip Miller, Martha Garrity
  • Patent number: 6706722
    Abstract: The invention relates to novel acridine derivatives of formula 1, to their preparation and to their use as medicaments, in particular for treating tumors.
    Type: Grant
    Filed: July 20, 2001
    Date of Patent: March 16, 2004
    Assignee: Zentaris AG
    Inventors: Peter Emig, Eckhard Günther, Bernd Nickel, Gerhard Bacher, Silke Baasner, Thomas Beckers, Beate Aue
  • Publication number: 20040038294
    Abstract: In accordance with the present invention, it has been discovered that introduction of hydrophilic sulfoalkyl substituents and/or hydrophilic linkers derived from homocysteic acid, cysteic acid, glycine peptides, tetraethylene oxide, and the like, offset the hydrophobicity of the acridinium ring system to produce a more soluble label which can be attached to an antibody at higher loading before precipitation and aggregation problems are encountered. Additional compounds described herein contain linkers derived from short peptides and tetraethylene oxide which increase aqueous solubility due to hydrogen bonding with water molecules. The present invention also embraces reagents for multiple acridinium labeling for signal amplification composed of a peptide bearing several acridinium esters with sulfonate groups at regularly spaced intervals for increased solubility. The invention also embraces assays employing the above-described compounds.
    Type: Application
    Filed: August 20, 2002
    Publication date: February 26, 2004
    Applicant: Quest Diagnostic Investments Incorporated
    Inventors: Ramon Evangelista, Martha Garrity
  • Patent number: 6664043
    Abstract: The present invention is generally directed to detectable chemiluminescent acridinium ester labels having hydrophilic modifiers; to compositions, complexes and/or conjugates which include such labels; and to processes for performing bioanalytical assays for target analytes which use such labels. Assays for folate, theophylline, and tobramycin (using such labels with hydrophilic modifiers such as nonionic polyethylene glycol and polyionic spermine disulfonate and polyionic spermine dicarboxylate) are described in detail.
    Type: Grant
    Filed: July 3, 2001
    Date of Patent: December 16, 2003
    Assignee: Bayer Corporation
    Inventors: Anand Natrajan, David Sharpe, Qingping Jiang
  • Publication number: 20030229073
    Abstract: The present invention provides a compound of the formula (I) and pharmaceutically acceptable salts having useful antiviral activity against viruses of the herpes family. In said formula, X=O, (CH2)m, S, SO, SO2, NH, NR8 or a chemical bond; Y=O, (CH2)m, S, SO, SO2, NH, NR8; Z=NH, O, NR8, S, SO, SO2. The remaining substituents are described in the specification.
    Type: Application
    Filed: July 5, 2002
    Publication date: December 11, 2003
    Inventors: Richard John Booth, Vara Prasad Venkata Nagendra Josyula, Annette Lynn Meyer, Bruce Allan Steinbaugh
  • Publication number: 20030207344
    Abstract: Ethers and esters of cyanohydrins that contain optically detectable moieties are highly effective for detecting, monitoring, and measuring the activity of enzymes that cause the cleavage of certain types of substrates. The cyanohydrins function as proaldehydes and proketones, spontaneously converting to aldehydes and ketones, respectively, which provide a large increase in optical detectability relative to both the starting esters and ethers and the cyanohydrins.
    Type: Application
    Filed: January 7, 2003
    Publication date: November 6, 2003
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Bruce D. Hammock, Guomin Shan, Rong Zhang
  • Patent number: 6630481
    Abstract: The present invention provides a series of novel bifunctional molecules based on viologen linked acridine, bisacridine and bisacridinium salts of the general formula 1 (1a, 1b, 1c and 1d) and or pharmaceutically acceptable derivatives thereof, which can be used as phototherapeutic and catalytic photoactivated DNA cleaving agents. These molecules are very stable and exhibit high solubility in buffer at physiological conditions. They undergo strong binding with DNA through intercalation and groove binding interactions and show remarkably high affinity for poly(dA).poly(dT) sequences. Upon photoactivation, they cleave DNA catalytically and selectively at guanine (G) sites in duplex DNA exclusively through cosensitization mechanism with a preference for 5′-G over 3′-G. They induce unusally high specificity of cleavage at G site of the AG two base bulge sequences.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: October 7, 2003
    Assignee: Council of Scientific and Industrial Research of India
    Inventors: Ramaiah Danaboyina, Varghese Eldho Nadukkudy, Joseph Joshy
  • Publication number: 20030092060
    Abstract: A novel chemiluminescent compound is provided. In one embodiment, the novel compound is employed in an assay to detect analytes. The assay to detect analytes includes the steps of binding the novel compound to the analyte and detecting the novel compound.
    Type: Application
    Filed: October 31, 2001
    Publication date: May 15, 2003
    Applicant: Quest Diagnostics Investments, Inc.
    Inventors: Miller Phillip P., Garrity Martha
  • Publication number: 20030089920
    Abstract: In accordance with the present invention, nanometer-scale reversible electronic switches are provided that can be assembled to make cross-bar circuits that provide memory, logic, and communications functions. The electronic switches, or crossed-wire devices, comprise a pair of crossed wires that form a junction where one wire crosses another at an angle other than zero degrees and at least one connector species connecting the pair of crossed wires in the junction. The junction has a functional dimension in nanometers, wherein at least one connector species and the pair of crossed wires forms an electrochemical cell.
    Type: Application
    Filed: November 7, 2002
    Publication date: May 15, 2003
    Inventors: Alexandre M. Bratkovski, Pavel Kornilovich, R. Stanley Williams, Xiao-An Zhang
  • Publication number: 20030045538
    Abstract: The present invention provides a series of novel bifunctional molecules based on viologen linked acridine, bisacridine and bisacridinium salts of the general formula 1 (1a, 1b, 1c and 1d) and or pharmaceutically acceptable derivatives thereof, which can be used as phototherapeutic and catalytic photoactivated DNA cleaving agents. These molecules are very stable and exhibit high solubility in buffer at physiological conditions. They undergo strong binding with DNA through intercalation and groove binding interactions and show remarkably high affinity for poly(dA).poly(dT) sequences. Upon photoactivation, they cleave DNA catalytically and selectively at guanine (G) sites in duplex DNA exclusively through cosensitization mechanism with a preference for 5′-G over 3′-G. They induce unusally high specificity of cleavage at G site of the AG two base bulge sequences.
    Type: Application
    Filed: February 28, 2001
    Publication date: March 6, 2003
    Applicant: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH of India
    Inventors: Ramaiah Danaboyina, Varghese Eldho Nadukkudy, Joseph Joshy
  • Publication number: 20030032801
    Abstract: A compound having the structural formula 1
    Type: Application
    Filed: May 7, 2001
    Publication date: February 13, 2003
    Inventors: Ai J. Lin, Jian Guan, Dennis E. Kyle, Wilbur K. Milhous
  • Patent number: 6512119
    Abstract: In accordance with the present invention, nanometer-scale reversible electronic switches are provided that can be assembled to make cross-bar circuits that provide memory, logic, and communications functions. The electronic switches, or crossed-wire devices, comprise a pair of crossed wires that form a junction where one wire crosses another at an angle other than zero degrees and at least one connector species connecting the pair of crossed wires in the junction. The junction has a functional dimension in nanometers, wherein at least one connector species and the pair of crossed wires forms an electrochemical cell. The connector species comprises a bistable molecule having a general formula given by The bistable molecules evidence high switching speed. Such molecules are essentially stable against switching due to thermal fluctuations.
    Type: Grant
    Filed: January 12, 2001
    Date of Patent: January 28, 2003
    Assignee: Hewlett-Packard Company
    Inventors: Alexandre M. Bratkovski, Pavel Kornilovich, R. Stanley Williams, Xiao-An Zhang
  • Publication number: 20020173651
    Abstract: This invention relates to process for producing annulated pyridine bases by reacting cyclic ketones with aliphatic aldehyde in presence of ammonia in gaseous phase in the presence of a catalyst. This process provides an eco-friendly, more economical and highly selective heterogeneous method.
    Type: Application
    Filed: March 27, 2001
    Publication date: November 21, 2002
    Applicant: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
    Inventors: Shivanand Janardan Kulkarni, Kondapuram Vijaya Raghavan, Radha Rani Vippagunta, Srinivas Nagabandi
  • Publication number: 20020119992
    Abstract: Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: 1
    Type: Application
    Filed: December 18, 2001
    Publication date: August 29, 2002
    Inventors: Harold G. Selnick, James C. Barrow, Philippe G. Nantermet, Peter D. Williams, Kenneth J. Stauffer, Philip E. Sanderson, Kenneth E. Rittle, Matthew M. Morrissette, Catherine M. Wiscount, Lekhanh O. Tran, Terry A. Lyle, Donnette D. Staas
  • Publication number: 20020103217
    Abstract: This invention relates to anti-inflammatory compounds, methods of making such compounds and methods of using such compounds having the following structure: 1
    Type: Application
    Filed: January 8, 2002
    Publication date: August 1, 2002
    Inventors: Malcolm K. Scott, Pauline J. Sanfilippo, Louis J. Fitzpatrick, Richard Cordova, Kevin Pan, Joseph Meschino
  • Patent number: 6417005
    Abstract: Fluoroionophores that are functionalised with reactive groups and correspond to the formula I—R1—F—R2—G, wherein I is a monovalen residue of an ionophore, wherein F is a divalent residue of a fluorophore, wherein G is a functional group and R1 and R2 are each independently of the other a direct bond or a bridging group. The fluoroionophores may be covalently bound to carrier materials and are used as active components in polymer membranes of optical sensors for the detection of ions. The sensors are distinguished by a long usable life and a high degree of sensitivity.
    Type: Grant
    Filed: December 7, 1998
    Date of Patent: July 9, 2002
    Assignee: Novartis AG
    Inventors: Steven Mark Barnard, Adrian Waldner, David Reinhoudt, Joseph Berger
  • Patent number: 6417402
    Abstract: The present invention relates to squaraine dye containing terminal aminoanthracene or acridine groups and to a process for preparation thereof.
    Type: Grant
    Filed: September 26, 2001
    Date of Patent: July 9, 2002
    Assignee: Council of Scientific and Industrial Research
    Inventors: Suresh Das, George Thomas Kakkudiyil, Biju Vasudevan Pillai, Santosh Unni, Suresh Velate
  • Patent number: 6414152
    Abstract: A compound for use as a chemiluminescent label in immunoassay comprises an aryl acridinium ester linked to an N-succinimidyl moiety. The compound is conveniently linked to a monoclonal antibody or other protein and is used in a two-site immunoassay for the quantitation of an antigen of interest, by initiation of the luminescent reaction and subsequent measurement of the photonic emission of the immune complex formed during the immunological reaction.
    Type: Grant
    Filed: October 24, 1994
    Date of Patent: July 2, 2002
    Assignee: University of Wales College of Medicine of Heath Park
    Inventors: Anthony Keith Campbell, James Stuart Woodhead, Ian Weeks
  • Patent number: 6413984
    Abstract: The invention concerns compounds of formula (I) wherein: A represents either a hydrogen atom or a hydroxyl group; B represents a pyrrolidin-2-yl (D) or 2-piperidyl (E), B capable of being substituted by one or two R5 groups; R1 represents a hydrogen atom, a C1-C6 alkyl, a C2-C6 alkenyl, a C1-C2 perfluoroalkyl or a C1-C6 fluoroalkyl group; R2, R3 or R4, independently of one another, represent a hydrogen atom, a C1-C6 alkyl, group or a C2-C6 alkenyl group, or R1 and R2 can together form a C1-C6 alkylene chain, or a C3-C6 alkenylene chain; R5 represents a C1-C6 alkyl group, and R6 represents a hydrogen atom, a C1-C6 alkyl group, a C2-C6 alkenyl group, C3-C6 cycloalkyl, C3-C6 cycloalkenyl or a benzyl.
    Type: Grant
    Filed: August 1, 2001
    Date of Patent: July 2, 2002
    Assignee: Sanofi-Synthelabo
    Inventors: Christophe Philippo, Alain Braun, Philippe R. Bovy
  • Patent number: 6410732
    Abstract: Synthetic processes and intermediates are disclosed for the preparation of N-arylacridancarboxylic acid derivatives. The derivatives are esters, thioesters, amides and sulfonimides. A key feature of the processes is the preparation of N-aryl substituted intermediates by formation of a bond between the nitrogen atom of the acridan ring and a carbon atom of another aromatic or heteroaromatic ring compound. The arylation reaction is catalyzed by a palladium catalyst. The N-arylacridancarboxylic acid derivatives are useful in methods for producing light and in assays for peroxidase enzymes and enzyme inhibitors and in assays employing enzyme-labeled specific binding pairs.
    Type: Grant
    Filed: January 25, 2001
    Date of Patent: June 25, 2002
    Assignee: Lumigen, Inc.
    Inventors: Hashem Akhavan-Tafti, Robert A. Eickholt, Richard S. Handley
  • Publication number: 20020058687
    Abstract: Therapeutically active compositions of matter are described which are useful for treating or preventing diseases and conditions comprising inflammatory diseases including joint inflammation, Crohn's disease, and inflammatory bowel disease; respiratory diseases such as chronic obstructive pulmonary disease (COPD) including asthma, chronic bronchitis, and pulmonary emphysema; infectious diseases including endotoxic shock and toxic shock syndrome; immune diseases including systemic lupus erythematosis and psoriasis; and other diseases including bone resorption diseases and reperfusion injury; wherein said composition of matter comprises a compound which is an inhibitor of phosphodiesterase isozyme 4 (PDE4) and wherein an indazole is one essential component of said compound's overall chemical structure, and wherein said indazole constitutes a bioisosteric replacement of a catechol component or functional derivative thereof in a known compound having the same said therapeutic activity and the same remaining said c
    Type: Application
    Filed: September 20, 1999
    Publication date: May 16, 2002
    Inventor: ANTHONY MARFAT
  • Publication number: 20020037254
    Abstract: The invention relates to conjugates, comprising a fluorescent compound and a carrier, wherein the compound and the carrier are connected via an acidic ester or an acidic amide bond and the compound has an excitation wavelength of 630 nm or more and/or 450 nm or less. The invention also relates to the production of said conjugates and to the use thereof.
    Type: Application
    Filed: August 4, 2000
    Publication date: March 28, 2002
    Inventors: HANNSJORG SINN, HANS-HERMANN SCHRENK, ANDREAS WUNDER, GERD STEHLE
  • Patent number: 6355803
    Abstract: This application relates to long-wavelength acridinium compounds having electron-donating groups, which may either be: (a) Part of an extended conjugation system attached by appropriate functional groups to the acridinium nucleus, with coplanarity of the attached functional group and the acridone moiety during light emission (geometry requirement), said functional group consisting of at least one aromatic ring and one electron-donating atom or group with an extra pair of electrons which can readily delocalize into the extended &pgr; system to which the heteroatom is directly attached or built into, and establish stable extended resonance with the electron-withdrawing carbonyl moiety of the light emitting acridone.
    Type: Grant
    Filed: August 10, 1999
    Date of Patent: March 12, 2002
    Assignee: Bayer Corporation
    Inventors: Anand Natrajan, Qingping Jiang, David Sharpe, Say-Jong Law
  • Publication number: 20010031869
    Abstract: Synthetic processes and intermediates are disclosed for the preparation of N-arylacridancarboxylic acid derivatives. The derivatives are esters, thioesters, amides and sulfonimides. A key feature of the processes is the preparation of N-aryl substituted intermendiates by formation of a bond between the nitrogen atom of the acridan ring and a carbon atom of another aromatic or heteroaromatic ring compound. The arylation reaction is catalyzed by a palladium catalyst. The N-arylacridancarboxylic acid derivatives are useful in methods for producing light and in assays for peroxidase enzymes and enzyme inhibitors and in assays employing enzyme-labeled specific binding pairs.
    Type: Application
    Filed: January 25, 2001
    Publication date: October 18, 2001
    Inventors: Hashem Akhavan-Tafti, Robert A. Eickholt, Richard S. Handley
  • Patent number: RE39047
    Abstract: A light emitting method of an acridinium ester, comprising reacting said acridinium ester and a superoxide anion, and a method of detecting a substance to be examined, comprising detecting a light emitted by reacting a superoxide anion with an acridinium ester used as a label am described. It is possible to carry out the reaction not under strongly alkaline conditions but around the neutral point and to generate strong luminescence which is stable over a long period of time.
    Type: Grant
    Filed: March 8, 2001
    Date of Patent: March 28, 2006
    Assignee: Mitsubishi Kagaku Iatron, Inc.
    Inventors: Masuo Aizawa, Michiko Ikariyama, Eiry Kobatake, Minoru Ogasawara, Mitsunao Tanaka, Yoshihito Ikariyama